Deep search
Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
    • Hotels
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent

News

FDA approves Yeztugo

CNBC on MSN · 14h
Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV
Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention medication, how the twice-yearly antiviral drug Yeztugo works, the importance of preventive medicine,
The Jerusalem Post on MSN · 2d
FDA approves Yeztugo: Gilead's new twice-yearly HIV prevention injection
He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the molecule lenacapavir, offers a more effective and less invasive prevention method,
Mint on MSN · 4d
Gilead's bi-annual HIV prevention jab gets FDA approval: How much does it cost and how it works? All you need to know…
Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent effectiveness in trials. Here's how it works, and what it costs.
2don MSN
Here’s what everyone should know about this new HIV prevention shot
Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.
Fierce Pharma
5d
FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending now

ISR-Iran agree to ceasefire?
US base in Qatar attacked
Thunder win NBA title
Lifts limits on deportations
Judge denies detention
Suicide attack in Syria
Social media post apology
OKs $400M stock buyback
Vetoes THC ban in Texas
Scrub each other clean?
Flight hits turbulence
On war powers resolution
News Corp extends contract
Ford recall
1st images of largest camera
Russian attack on Kyiv
Takes over as IOC president
Tops box office again
D. Wayne Lukas hospitalized
To hear case of Rastafarian
Suspected MI shooter killed
Compass sues Zillow
Media rights deal with CBS
Man killed by lightning
Bowman backs July rate cut
LSU wins NCAA baseball title
2-year extension with Bruins
Bad Company guitarist dies
Italian sphere sculptor dies
A’s celebrate groundbreaking
Scrubs news of Jony Ive deal
Suffers Achilles injury
Ends deal with Hims & Hers
FL immigration law petition
Feedback
© 2025 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices
  • Consumer Health Privacy